Abstract 2054
Background
Oncology patients with advanced disease frequently undergo Radiation to relieve symptoms such as pain and dyspnoea. These patients have been treated by different health professionals in multiple, complexed and long-term treatments. The goal of this study was to investigate the possibility to help and improve the quality of life of these patients.
Trial design
In the present study, 32 patients participated and were evaluated prospectively. The main criteria for their participation were the following: oncology patients >18 years old with a satisfactory level of verbal communication and advance cancer receiving radiotherapy. EORTC questionnaires (QLQ-C30) and questionnaire for problems and needs for palliative care PNCP-Center for the Quality of Care of the WOK research were used.The quality of life of these patients was assessed prior the beginning of the treatment and that was taken as a quality of life baseline level as well as at the end of their treatment. The present study was conducted from June 2018 to December 2018 in the Radiotherapy Department of "Hygeia" Hospital in Greece. Of the 32 patients who were evaluated 11 were women and 21 were men. Their average age was 65 years old. Also 84,4% of these patients had external help (family, caretaker). A significant improvement in the quality of life was observed only in patients who had home help for 4 hours daily (p.value 0,006).Men seemed to improve the quality of life after treatment (p.value 0,005).The patients reported their palliative care needs in the following rating scale: financial and phychological issues, autonomy, daily activities, spiritual issues, organic symptoms and need for information ,all of which will be presented in detail. Those who have difficulty completing tasks need or depent on others and ask for professional help (p.value 0,001)Radiation therapy alleviates the organic symptoms of patients with advanced disease, but it does not cover their needs that have become more important to them than their organic symptoms. Care for these patients needs a more specialized approach which incorporates the principles of palliative care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract